Close Menu

Investing in DNA

When it comes to investing, sometimes thinking small is best, says Forbes' Yuval Bar-Or. Progress in technology and innovative products associated with DNA sequencing and the human genome could mean investment opportunities. As the $1,000 (or cheaper) genome approaches, the implications are "at once wondrous and disturbing," says Bar-Or, who hold investments in Illumina and Life Technologies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.